TP53 and B-cell chronic lymphocytic leukemia: In a multicenter Swedish study providing real-life data from 95 CLL patients (median age: 69 years, del(17p)/TP53 mutation in 63%, Rai stage 3/4 in 65%), the authors reported that once-a-day ibrutinib treatment was well tolerated and associated with an ORR of 84%, PFS of 77%, and OS rate of 83% at a median follow-up of 10.2 months [23].